Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/28/2026 | $262.00 | Equal-Weight → Overweight | Morgan Stanley | |
| 11/13/2025 | $230.00 | Sector Outperform | Scotiabank | |
| 10/20/2025 | $203.00 | Neutral → Outperform | Daiwa Securities | |
| 10/3/2025 | $212.00 | Equal Weight → Overweight | Wells Fargo | |
| 9/23/2025 | $206.00 | Neutral → Buy | Guggenheim | |
| 7/23/2025 | Hold → Buy | Erste Group | ||
| 5/13/2025 | $153.00 | Outperform → Market Perform | Leerink Partners | |
| 12/30/2024 | $15.00 | Buy | H.C. Wainwright |
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
In the news release, Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE), issued 03-Mar-2026 by Johnson & Johnson over PR Newswire, we are advised by the company that the last sentence of the fifth paragraph has been amended. The complete, corrected release follows: Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timelineThe designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity
The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timelineThe designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosusSPRING HOUSE, Pa., March 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that nipocalimaba was
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00
Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00
Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of
AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program
GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i
GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of service to the company and its shareholders. "For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent's mission to protect and save lives," said Joe Papa, president and CEO of Emergent. "On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best." Dr. Sullivan served on Emergent's Board of Directors since 2006, and most recently served as chair of the
Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o
SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)